olfactory receptor family 8 subfamily G member 5Genealiases: OR11-298 · OR8G5P · OR8G6
Q-omics provides the consensus-scored OR8G5 profile across patient tissues and cancer cell-line models. OR8G5 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, OR8G5 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, OR8G5 RNA expression shows 5,882 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, COAD, and STAD as cancer lineages where OR8G5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR8G5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR8G5 survival associations across molecular data types. OR8G5 RNA expression shows survival associations in the most cancer types (12), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR8G5 RNA expression–survival associations across cancer types. High OR8G5 expression shows unfavorable associations in CESC, UCS, LIHC, STAD and PAAD, but favorable associations in SKCM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for OR8G5 RNA expression.
This table summarizes OR8G5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR8G5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR8G5 shows lower tumor expression in COAD and READ and higher tumor expression in KIRP, THCA and LIHC. The COAD box plot shows higher OR8G5 RNA expression in normal versus tumor tissue (log2 FC = −0.115, t-test p < 0.001).
This table shows molecular features associated with OR8G5 in patient tissues and cancer cell lines. In patient samples, OR8G5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR8G5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_NSCLC_LUAD.
